The objective of this ongoing study is to evaluate and delineate the long-term therapeutic effects of enzyme replacement therapy in Gaucher disease in affected children and adults. In addition, efforts are directed to identifying and delineating the causes for and treatment of adverse events related to enzyme therapy, as well as determining the effective dose in individual patients. To date, we have enrolled over forty patients in this protocol from the Cincinnati greater metropolitan area and from around the world. We have established normative data for the expected responses for patients during the first six, twelve and twenty-four months of therapy using either Ceredase (alglucerase for injection from placenta) or Cerezyme (imiglucerase for injection from recombinant sources), and have found that the responses are no different in either treatment group. The same degree of variability, which is very high, is observed with both of the drugs and we have found no specific correlation with age of onset or initiation of therapy, genotype of the individual patients, ethnic extraction, nor initial severity of disease. In general, the hepatic and splenic volumes decrease to about twenty to forty percent of initial volume by two years, the hematologic abnormalities including anemia and thrombocytopenia diminish and become normalized within approximately two to three years, and, in children with growth retardation, normal growth patterns are reestablished within two years. Documentation of improvement in architectural bone disease has been slow and unconvincing. Indeed, based on this result, we have initiated a new protocol that evaluates the effectiveness of alendronate in combination with enzyme therapy on the architectural bone disease in osteopenia of Gaucher disease. Approximately three to five percent of our patients develop minor adverse events, including hives, pruritis, erythema, and headache during or shortly following the infusion. These are managed by decreasing infusion rates and/or pretreatment with antihistamine. We have had no anaphylactic or anaphylactoid reactions. Of the fifteen percent of treated patients that develop antibodies during the course of therapy, two were found to have neutralizing antibodies that altered their responsiveness to enzyme therapy. In both cases, poor to absent response to enzyme infusions was noted and this led to the detection of the neutralizing antibodies. In one patient, a very high dose cytoxin protocol was used to induce tolerance. After two and a half years of high dose therapy, she has tolerized with the absence of both antibodies and neutralizing activity. Ongoing studies are directed to defining the time for tolerization in all patients who develop antibodies; currently this appears to be about twenty-two to twenty-four months. In addition, ongoing studies are directed to defining the parameters that account for the massive variability and response to enzyme therapy in affected patients.

Project Start
2000-12-01
Project End
2001-11-30
Budget Start
Budget End
Support Year
8
Fiscal Year
2001
Total Cost
$28,540
Indirect Cost
Name
Cincinnati Children's Hospital Medical Center
Department
Type
DUNS #
071284913
City
Cincinnati
State
OH
Country
United States
Zip Code
45229
Natarajan, Girija; Shankaran, Seetha; Laptook, Abbot R et al. (2018) Association between sedation-analgesia and neurodevelopment outcomes in neonatal hypoxic-ischemic encephalopathy. J Perinatol 38:1060-1067
Askie, Lisa M; Darlow, Brian A; Finer, Neil et al. (2018) Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. JAMA 319:2190-2201
DiFrancesco, Mark W; Shamsuzzaman, Abu; McConnell, Keith B et al. (2018) Age-related changes in baroreflex sensitivity and cardiac autonomic tone in children mirrored by regional brain gray matter volume trajectories. Pediatr Res 83:498-505
Autmizguine, Julie; Tan, Sylvia; Cohen-Wolkowiez, Michael et al. (2018) Antifungal Susceptibility and Clinical Outcome in Neonatal Candidiasis. Pediatr Infect Dis J 37:923-929
Jilling, Tamas; Ambalavanan, Namasivayam; Cotten, C Michael et al. (2018) Surgical necrotizing enterocolitis in extremely premature neonates is associated with genetic variations in an intergenic region of chromosome 8. Pediatr Res 83:943-953
Zeller, Meg H; Pendery, Emma C; Reiter-Purtill, Jennifer et al. (2017) From adolescence to young adulthood: trajectories of psychosocial health following Roux-en-Y gastric bypass. Surg Obes Relat Dis 13:1196-1203
Srinivasan, Lakshmi; Page, Grier; Kirpalani, Haresh et al. (2017) Genome-wide association study of sepsis in extremely premature infants. Arch Dis Child Fetal Neonatal Ed 102:F439-F445
Shankaran, Seetha; Laptook, Abbot R; McDonald, Scott A et al. (2017) Acute Perinatal Sentinel Events, Neonatal Brain Injury Pattern, and Outcome of Infants Undergoing a Trial of Hypothermia for Neonatal Hypoxic-Ischemic Encephalopathy. J Pediatr 180:275-278.e2
Hogan, Jonathan J; Palmer, Matthew D; Loren, Alison W et al. (2017) Quiz Page May 2017: CKD and Nephrotic Syndrome After Allogeneic Hematopoietic Cell Transplantation. Am J Kidney Dis 69:A10-A13
Di Fiore, Juliann M; Martin, Richard J; Li, Hong et al. (2017) Patterns of Oxygenation, Mortality, and Growth Status in the Surfactant Positive Pressure and Oxygen Trial Cohort. J Pediatr 186:49-56.e1

Showing the most recent 10 out of 502 publications